-
Press ReleasesMEDIA INQUIRIES Media@BriiBio.com
-
Brii Biosciences Expands Therapeutic Focus to Include Neurosciences with Addition of John Kraus, M.D., Ph.D.
December 03, 2019
- Dr. Kraus to lead newly-created Neurosciences Therapy Area
- Zhijian Chen, Ph.D., named Strategic Scientific Advisor -
Brii Biosciences Expands Infectious Disease Pipeline
November 21, 2019
-Three partnerships focused on novel programs for treatment-resistant bacterial infections and diseases
-Company pipeline now includes up to 12 partnered assets, in addition to internal development programs
-Infectious disease focus will address disproportional unmet need in China and support global public health -
VBI Vaccines and Brii Biosciences Initiate Phase 1b/2a Study of BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B Infection
November 14, 2019
-Novel recombinant, protein-based immuno-therapeutic for the treatment of chronic hepatitis B virus (HBV) infection
-Two-part, dose-escalation study expected to enroll up to 65 patients
-Initial data expected in H2 2020
